The antitumor efficacy of anti-p21Ras scFv mediated by the dual-promoter-regulated recombinant adenovirus KGHV300.
Ras mutations and overexpression of the Ras protein, p21Ras, are main causes of cancer development and progression, which has made the Ras gene and p21Ras important targets for therapy of Ras-driven cancers. We previously prepared recombinant adenovirus KGHV100 based on replication-defective adenovirus type 5, which could intracellularly express anti-p21Ras single chain fragment viable antibodies (scFv) and repress tumor growth in vitro and in vivo. However, the anti-tumor effects of this anti-p21Ras scFv were limited by short-term scFv expression due to a replication defect of KGHV100. To enhance the anti-tumor efficacy and safety of anti-p21Ras scFv, the present study constructed a dual-promoter-regulated recombinant adenovirus KGHV300 that carried anti-p21Ras scFv. In KGHV300, the expression levels of the essential replication genes E1a and E1b, were controlled by the human telomerase reverse transcriptase promoter and the hypoxia response element, respectively, and the anti-p21Ras scFv gene was controlled by the cytomegalovirus promoter. The conditional replication of KGHV300 and its antitumor efficacy were characterized in several tumor cell lines in vitro and in xenograft models of human breast cancer in nude mice. TCID50 assay demonstrated that KGHV300 could replicate in tumor cell lines but not in normal cell lines. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay indicated that the growth of tumor cells was effectively inhibited by KGHV300 infection. In MDA-MB-231 tumor xenograft models, KGHV300 effectively and significantly inhibited tumor growth and induced apoptosis of tumor cells. We concluded that the recombinant adenovirus KGHV300 may be a more potent and safer antitumor therapeutic for Ras-driven cancer biotherapy.
Department of Pathology, Kunming General Hospital, Kunming, Yunnan Province, China.
X Y
XY
Pan
Graduate School, Kunming Medical University, Kunming, Yunnan Province, China.
X J
XJ
Liu
Department of Genetics, Medical College, Kunming University of Science and Technology, Kunming, Yunnan Province, China.
J
J
Li
Graduate School, Kunming Medical University, Kunming, Yunnan Province, China.
S J
SJ
Zhen
Graduate School, Kunming Medical University, Kunming, Yunnan Province, China.
D X
DX
Liu
Department of Pathology, Kunming General Hospital, Kunming, Yunnan Province, China.
Q
Q
Feng
Department of Pathology, Kunming General Hospital, Kunming, Yunnan Province, China.
W X
WX
Zhao
Department of Genetics, Medical College, Kunming University of Science and Technology, Kunming, Yunnan Province, China.
Y
Y
Luo
Biotechnique College, Southern Medical University, Guangzhou, Guangdong Province, China.
Y L
YL
Zhang
Biotechnique College, Southern Medical University, Guangzhou, Guangdong Province, China.
H W
HW
Li
Department of Pathology, Kunming General Hospital, Kunming, Yunnan Province, China.|Graduate School, Kunming Medical University, Kunming, Yunnan Province, China.|Department of Genetics, Medical College, Kunming University of Science and Technology, Kunming, Yunnan Province, China.
J L
JL
Yang
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D017209:Apoptosis; D005260:Female; D045325:HCT116 Cells; D057809:HEK293 Cells; D056945:Hep G2 Cells; D006801:Humans; D007167:Immunotherapy; D061986:MCF-7 Cells; D008325:Mammary Neoplasms, Experimental / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D011401:Promoter Regions, Genetic; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics / Q000276:immunology*; D057127:Single-Chain Antibodies / Q000276:immunology*
D057127:Single-Chain Antibodies; D016283:Proto-Oncogene Proteins p21(ras)